21 CFR 801 Medical Device Labeling Requirements: What Startups and Regulatory Teams Must Know

Why Labeling Is Your First Line of Regulatory Defense

Medical device labeling is not a packaging afterthought. Under FDA's regulatory framework, labeling is a primary enforcement mechanism — and noncompliant labeling can trigger warning letters, import alerts, and even product recalls before your device ever reaches a patient. For startup founders navigating their first submission and for seasoned regulatory professionals managing a product portfolio, understanding the full scope of 21 CFR Part 801 is non-negotiable.

This post breaks down what the regulation actually requires, where companies most often go wrong, and what a defensible labeling strategy looks like in practice.

The Regulatory Foundation: What 21 CFR Part 801 Covers

21 CFR Part 801 establishes the general labeling requirements for medical devices distributed in interstate commerce. The term "labeling" under 21 CFR 801.1 is far broader than most founders realize — it encompasses not just the physical label affixed to the device, but all written, printed, or graphic matter that accompanies the device. That includes instructions for use (IFU), package inserts, promotional brochures, and in many cases, digital content linked to a physical product.

The regulation is divided into several subparts, each addressing a distinct labeling context:

• Subpart A (General Labeling Provisions): Covers prominence requirements, false or misleading labeling, and the definition of adequate directions for use under 21 CFR 801.5.
• Subpart B (Labeling Requirements for Prescription Devices): Governs Rx device labeling under 21 CFR 801.109, including the required caution statement restricting sale to or on the order of a licensed practitioner.
• Subpart C (Labeling Requirements for Over-the-Counter Devices): Addresses directions for use for devices available without a prescription.
• Subpart H (Special Requirements for Specific Devices): Includes requirements for hearing aids, contact lenses, and other device-specific labeling mandates.

Core Labeling Elements FDA Expects to See

Regardless of device classification, certain foundational elements must appear on your label. Under 21 CFR 801.1, labels must be prominently placed and in terms the intended user can read and understand. At minimum, a compliant device label typically includes:

• Name and place of business of the manufacturer, packer, or distributor (21 CFR 801.1)
• Quantity of contents (21 CFR 801.8)
• Adequate directions for use, unless an exemption applies (21 CFR 801.5 and 801.109 for Rx devices)
• Appropriate caution or warning statements where required
• Unique Device Identifier (UDI) in compliance with 21 CFR Part 830 and the UDI rule finalized in 2013
• Lot or batch number, manufacturing date, and expiration date where applicable under 21 CFR 801.18

For devices subject to 510(k) clearance or PMA approval, the cleared or approved indications for use must be accurately reflected. Labeling claims that exceed the cleared intended use create significant regulatory and liability exposure — this is one of the most common issues FDA identifies during inspections and pre-market review.

UDI Compliance: Still a Gap for Many Companies

The Unique Device Identification (UDI) system under 21 CFR Part 830 and 21 CFR 801.20 continues to trip up smaller device companies. Class II devices have been subject to UDI requirements since 2015, and Class I devices since 2020. Your label must carry a UDI in both human-readable interpretation (HRI) and machine-readable form (barcode or RFID), and device information must be submitted to FDA's GUDID database. Noncompliance here is straightforwardly observable during an FDA inspection and routinely cited in Form 483 observations.

Common Labeling Mistakes That Invite FDA Scrutiny

Based on enforcement trends and warning letter data, the following labeling deficiencies appear repeatedly:

• Intended use scope creep: Marketing materials or IFUs that imply indications not cleared by FDA effectively create a new intended use, potentially making the device adulterated or misbranded under 21 USC 351 and 352.
• Inadequate directions for use: Directions must be sufficient for a layperson to use the device safely and for its intended purpose, unless the Rx exemption under 21 CFR 801.109 applies and all conditions of that exemption are satisfied.
• Non-prominent or illegible labeling: The conspicuousness standard under 21 CFR 801.15 requires that required label statements appear with sufficient prominence relative to other label content.
• Failure to update labeling post-clearance: Device modifications that affect safety or effectiveness may require a new 510(k) and updated labeling — failing to align the two is a serious compliance gap.

International Labeling and the Global Picture

If you distribute outside the US, 21 CFR 801 requirements stack on top of international obligations. The FDA's guidance on labeling recommendations for investigational devices and the agency's alignment with ISO 15223-1 symbols provide a framework for symbol use on device labels — but symbols do not replace required text statements unless FDA has specifically recognized the symbol for that purpose. Review the FDA Labeling — Regulatory Requirements for Medical Devices guidance document as a baseline reference when building your global labeling strategy.

Build Labeling Into Your Design Controls — Not After

The most defensible labeling programs are built upstream, during design and development under your 21 CFR Part 820 (QSR) or ISO 13485 design controls process. Treat labeling as a design output. Conduct human factors validation on your IFU. Maintain revision-controlled labeling master records. And ensure your labeling review process includes regulatory, clinical, and quality sign-off before any label version is released to manufacturing.

Reactive labeling remediation is expensive. A warning letter response or recall correction is far more disruptive than getting it right during development.

Ready to Pressure-Test Your Labeling Strategy?

At ADB Consulting & CRO Inc., we work with medical device startups and established manufacturers to build labeling programs that withstand FDA scrutiny — from first-in-human labeling for investigational devices to commercial launch labeling aligned with your 510(k) clearance. Whether you are preparing for a pre-submission meeting or responding to a deficiency letter citing labeling issues, our team brings the regulatory depth and practical experience to move you forward.

Book a free discovery call with Andre Butler and the ADB team at adbccro.com. Let's review your labeling, identify your gaps, and build a clear path to compliance.